We investigate whether treatment with Ro5 attenuates neuroinflammation, tau pathologies, and brain atrophy using clinically translatable, non-invasive neuroimaging approaches including positron emission tomography (PET) and volumetric magnetic resonance imaging (MRI). The gene discussed is MAPT; the disease is Brain atrophy.